Citation Impact
Citing Papers
An integrated map of genetic variation from 1,092 human genomes
2012 StandoutNature
Clinical trials in primary hepatocellular carcinoma: current status and future directions
1988
Hepatocellular carcinoma
2018 Standout
Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.
1996 Standout
Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin
1991
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
2003 Standout
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin
1999 Standout
Nanoparticles in cancer therapy and diagnosis
2002 Standout
Single-Dose Toxicity Study of Hepatic Intra-arterial Infusion of Doxorubicin Coupled to a Novel Magnetically Targeted Drug Carrier
2001
A global view of hepatocellular carcinoma: trends, risk, prevention and management
2019 Standout
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
2021 Standout
Taxonomizing, sizing, and overcoming the incidentalome
2012
Management of Hepatocellular Carcinoma *
2005 Standout
Clinical Pharmacokinetics of Doxorubicin
1988
Superparamagnetic iron oxide nanoparticles (SPIONs): Development, surface modification and applications in chemotherapy
2010 Standout
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
2001 Standout
Advances and Challenges of Liposome Assisted Drug Delivery
2015 Standout
Prognostic Factors in Patients With Hepatocellular Carcinoma Receiving Systemic Chemotherapy
1992
Chronic hepatitis B
2007 Standout
Recombinant α2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial
1989
Doxorubicin clearance in the obese.
1988
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing
2013 Standout
Exome sequencing as a tool for Mendelian disease gene discovery
2011
Doxil® — The first FDA-approved nano-drug: Lessons learned
2012 Standout
Hepatocellular carcinoma pathogenesis: from genes to environment
2006 Standout
Nonresectional therapies for hepatocellular carcinoma
1997
Hepatocellular carcinoma
2022 Standout
Clinical pharmacokinetics of doxorubicin in hepatoma patients after a single intravenous injection of free or nanoparticle-bound anthracycline
1989
Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer
2005
Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma.
2009
Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients
1985 Standout
Applications of magnetic nanoparticles in biomedicine
2003 Standout
Traditional Chinese medicine as a cancer treatment: Modern perspectives of ancient but advanced science
2019 Standout
Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone
2016
Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2
2013 Standout
Hepatocellular carcinoma
2000
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Systemic chemotherapy for hepatocellular carcinoma
1992
Works of Mark Tong being referenced
Automated validation of genetic variants from large databases: ensuring that variant references refer to the same genomic locations
2011
Doxorubicin (75 mg/m2) for hepatocellular carcinoma: clinical and pharmacokinetic results.
1984